dapansutrile inhibitor nucleotidebinding domain leucinerich repeat pyrin domain containing receptor inflammasome defined immune system receptor induces inflammation activation caspase caspase triggered damaged cells microbial pathogens canonical inflammasome comprises apoptosis speclike protein asc figure inflammasome forms binding pattern recognition receptors prrs damage associated molecular patterns damps activate caspase signals secretion proinflammatory cytokines resulting constant activation inflammasome believed play direct indirect role acute arthritis atherosclerosis various neurodegenerative diseases multiple sclerosis ms alzheimers disease ad parkinsons disease drug developed olactec therapeutics purpose decreasing peripheral inflammation binding protein inhibiting formation inflammasome interestingly dapansutrile also found reduce levels pro inflammatory cytokines without interfering tnfα stressed cells system ignite inflammasome turn produces secretion inflammatory cytokines dapansutrile tested clinical trials proposed beneficial compound remedy osteoarthritis gouty nevertheless preclinical research proposed dapansutrile potentially beneficial heart failure multiple dapansutrile βsulfonyl nitrile compound four carbon seven hydrogen one nitrogen two oxygen one sulfur atom figure molecular formula compound carries molecular weight gmol compound acknowledged names dapansutrile mm dmso nm ethanol synthesized alkylation sodium methanesulfinate reaction produces crude methylsulfonylpropionitrile purified dissolution acetone filtration sodium bromide biproduct solvent exchange via distillation recrystallization dapansutrile denoted βsulfonyl nitrile molecule mechanism action induces pinner reaction initiated reacting thiols alcohols amines thus leading formation thiomidates imidates amidines nitrile group still denoted covalent noncovalent irreversible nonreversible inhibitor currently studies nevertheless researchers believe dapansutrile promotes inhibition covalent bonds figure dapansutrile targets inhibition atpase thus blocks activation inflammasomes asc interaction thereby preventing assembly inflammasome inflammatory signals drug also inhibits pyroptosis nevertheless drug impact mrna levels asc research dapansutrile presents compound solely inhibits inflammasome murine macrophages used stimulated lipopolysaccharides either flagellin dsdna analog polydadt activate inflammasomes aim respectively dapansutrile added found difference release tnfα cytokines inflammasomes known targets dapansutrile include several phosphorylated kinases src fyn hck human monocyte derived macrophages hmdm cells stimulated lipopolysaccharide nigericin dapansutrile added found reduction phosphorylated kinases vitro human derived macrophages cultured study effect dapansutrile cytokine production found dapansutrile µm dose inhibited secretion levels drug also found selectively inhibit pyroptosis vivo phase one clinical trial subjects conducted establish safety dapansutrile daily mean plasma concentration maximum cmax single oral dose dapansutrile ngml dose ngml mg dose ngml mg dose figure dapansutrile also studied given repeatedly per day days dose either mg mg mg subjects mean plasma concentration day ngml mg dose ngml mg dose ngml mg marchetti et al study seven subjects reported adverse events five cases single dose study two cases multiregimen group however adverse effects considered unrelated subjects presented changes blood pressure systolic diastolic urinalysis heart rate liver function enzymes acute phase proteins cohort trial daily mg dosing multiple sclerosis multiple sclerosis ms neurodegenerative disease characterized immune system deteriorating myelin myelin damage leads disruption neuronal signaling dysregulrated inflammatory dapansutrile used experimental autoimmune encephalomyelitis eae mouse model understand possible underlying effects ms found mice fed dapansutrile diet protected mice demyelination spinal cord well decreased levels interleukins currently unclear whether drug could inhibit microglial reactivity currently known benefits aid prevention dementia cognitive gouty arthritis gouty arthritis inflammatory joint disorder partly induced activation inflammasome excess activation leads gout due excess uric acid blood promotes formation uric acid crystals joints uric acid known danger signal induce cleavage signal animal model experiments two murine models used validate dapansutrile drug beneficial acute joint inflammation injected zymosan monosodium urate crystals order induce gouty arthritis mice either injected intraperitoneally diet essence drug reduced joint inflammation well interleukin demonstrating therapeutic benefit disease clinical trials clinical trials olatec therapeutics also conducted phase trials dapansutrile given subjects gouty acute myocardial infarction heart attack one major downstream effects coronary artery disease possibility acute myocardial infarction heart mouse models dapansutrile found decrease infarct size dosedependent heart failure olatec therapeutics conducted phase clinical trial dapansutrile potential therapeutic systolic heart carried phase double blinded study total subjects assess drugs safety pharmacodynamics drug given capsule form subjects divided cohorts cohort subjects taking oral capsule mg dapansutrile subjects given placebo capsule although completion date clinical trial november results study yet severe acute respiratory syndrome coronavirus dapansutrile proposed number scientists measure reduce cardiovascular outcomes seem brought rationale behind using dapansutrile inhibit inflammasome reduce chances cytokine storm seems cause multiorgan failure subjects shown increased concentration proinflammatory cytokines resulting cytokine storm thus producing exhaustion activates cytokines key players inflict myocardial damages acute respiratory distress syndrome ards inhibition found deter thus dapansutrile proposed possible mediator relief prevent symptoms effects httpsenwikipediaorgwikidapansutrile